206 related articles for article (PubMed ID: 37233897)
1. Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T; Okubo Y; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Uehara N; Handa T; Tanaka M; Zhang W; Paris M; Murakami M
Am J Clin Dermatol; 2023 Sep; 24(5):837-847. PubMed ID: 37233897
[TBL] [Abstract][Full Text] [Related]
2. Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.
Okubo Y; Terui T; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Kimura T; Shimauchi J; Zhang W; Amouzadeh H; Murakami M
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38896381
[TBL] [Abstract][Full Text] [Related]
3. Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis.
Spencer RK; Elhage KG; Jin JQ; Davis MS; Hakimi M; Bhutani T; Liao W
Dermatol Ther (Heidelb); 2023 Feb; 13(2):437-451. PubMed ID: 36609960
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
Kt S; Thakur V; Narang T; Dogra S; Handa S
Am J Clin Dermatol; 2021 May; 22(3):415-423. PubMed ID: 33712987
[TBL] [Abstract][Full Text] [Related]
5. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Wilsmann-Theis D; Kromer C; Gerdes S; Linker C; Magnolo N; Sabat R; Reich K; Mössner R
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2045-2050. PubMed ID: 34077577
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.
Terui T; Kobayashi S; Okubo Y; Murakami M; Zheng R; Morishima H; Goto R; Kimura T
JAMA Dermatol; 2019 Oct; 155(10):1153-1161. PubMed ID: 31268476
[TBL] [Abstract][Full Text] [Related]
7. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
Bissonnette R; Haydey R; Rosoph LA; Lynde CW; Bukhalo M; Fowler JF; Delorme I; Gagné-Henley A; Gooderham M; Poulin Y; Barber K; Jenkin P; Landells I; Pariser DM
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):403-410. PubMed ID: 29055155
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
9. Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.
Okubo Y; Morishima H; Zheng R; Terui T
J Dermatol; 2021 Dec; 48(12):1838-1853. PubMed ID: 34453358
[TBL] [Abstract][Full Text] [Related]
10. Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.
Burden AD; Bissonnette R; Navarini AA; Murakami M; Morita A; Haeufel T; Ye B; Baehner F; Terui T
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2279-2297. PubMed ID: 37731086
[TBL] [Abstract][Full Text] [Related]
11. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study.
Reich K; Graff O; Mehta N
Br J Dermatol; 2016 Jun; 174(6):1277-81. PubMed ID: 26800106
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M
J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Mrowietz U; Barker J; Conrad C; Jullien D; Gisondi P; Flower A; Reddy J; Paris M; Picard H; Jardon S; Augustin M
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):348-355. PubMed ID: 36300769
[TBL] [Abstract][Full Text] [Related]
15. Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study.
Kato N; Takama H; Ando Y; Yanagishita T; Ohshima Y; Ohashi W; Akiyama M; Watanabe D
Int J Dermatol; 2021 May; 60(5):570-578. PubMed ID: 33454961
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis.
Bissonnette R; Maari C; Tsianakas A; Reid D; McCutchan S; Baumgartner S; Mackay J; Bhakta N
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2179-2193. PubMed ID: 34716902
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
Stein Gold L; Papp K; Pariser D; Green L; Bhatia N; Sofen H; Albrecht L; Gooderham M; Chen M; Paris M; Wang Y; Callis Duffin K
J Am Acad Dermatol; 2022 Jan; 86(1):77-85. PubMed ID: 34343599
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
Merola JF; Parish LC; Guenther L; Lynde C; Lacour JP; Staubach P; Cheng S; Paris M; Picard H; Deignan C; Jardon S; Chen M; Papp KA
J Am Acad Dermatol; 2024 Mar; 90(3):485-493. PubMed ID: 37852306
[TBL] [Abstract][Full Text] [Related]
20. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]